Risk for cytomegalovirus disease in patients receiving polymerase chain reaction-based preemptive antiviral therapy after allogeneic stem cell transplantation depends on transplantation modality.
Hebart
H
H
Brugger
W
W
Grigoleit
U
U
Gscheidle
B
B
Loeffler
J
J
Schäfer
H
H
Kanz
L
L
Einsele
H
H
Sinzger
C
C
D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D003587:Cytomegalovirus / Q000235:genetics / Q000254:growth & development / Q000302:isolation & purification*; D003586:Cytomegalovirus Infections / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology* / Q000209:etiology / Q000635:transmission; D005260:Female; D017245:Foscarnet / Q000627:therapeutic use*; D015774:Ganciclovir / Q000627:therapeutic use*; D019337:Hematologic Neoplasms / Q000150:complications / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D016867:Immunocompromised Host; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D012306:Risk; D019172:Transplantation Conditioning / Q000009:adverse effects; D014182:Transplantation, Autologous / Q000009:adverse effects; D014184:Transplantation, Homologous / Q000009:adverse effects*; D014775:Virus Activation
D000998:Antiviral Agents; D017245:Foscarnet; D015774:Ganciclovir